Tumor bioimmunotherapy CIK cells, DC-CIK cells, NK cells, Tcm cells transfusion, combined with epithelial immune modulation, new anti-tumor antibodies, cytokines and other latest international anti-tumor bioimmune comprehensive treatment, to develop individualized immunotherapy program for patients with all stages of tumor. It mainly includes interleukins, thymidine, interferon and other new cytokines, which provide important adjuvant therapy for patients with all stages of liver cancer through non-specific activation of anti-tumor immunity. Cytokine therapy has been clinically applied in our center for many years, with relatively mature technology, high feasibility, controllable side effects and remarkable efficacy. Antibody-based tumor targeting therapy: Humanized antibodies are the most important class of drugs in tumor targeting therapy, and there are three major classes of antibody drugs that have been applied in clinical practice: a. Antibodies targeting tumor cell surface signal receptors. For example, cetuximab and panitumumab can specifically bind to EGFR receptors on the surface of tumor cells and achieve efficient and specific killing of tumors through antigen-induced ADCC and CDC effects. Tumor cell apoptosis; Second, antibodies targeting tumor angiogenesis. For example, bevacizumab (anti-VEGF), recombinant human vascular endothelial inhibitor, etc., they block tumor angiogenesis and thus make the tumor lack the necessary nutrients for growth and produce anti-tumor effects; third, immunomodulatory antibodies (immune checkpoint inhibitors). Such as antibodies targeting immune checkpoint molecules PD-1, CTLA4, etc. Currently, these antibodies have made significant progress in the treatment of various solid tumors. In a recent clinical trial published in the journal NJEM, the combination of anti-PD-1/ CTLA4 antibodies achieved an objective response rate of more than 50% in the treatment of advanced melanoma, and some patients achieved long-term tumor-free survival. The development of hepatocellular carcinoma is clearly characterized by a large amount of tumor angiogenesis, and the second class of anti-angiogenic antibodies can be applied directly to our patients. Previous studies in our center clearly found that CTL cells in hepatocellular carcinoma patients have significant upregulation of PD-1, suggesting that there is an upregulation of anti-tumor immunity in hepatocellular carcinoma patients, and the third class of immune checkpoint antibody drugs can also be used in hepatocellular carcinoma patients in our center. We are actively coordinating with international leading medical centers such as NIH, Mayo Clinic Oncology Center, University of California Medical School Oncology Center, and Israel’s West Jaffa Medical Center to introduce the above drugs into our center for liver cancer treatment by means of clinical trials or outsourced drugs. Cell therapy: Currently, we can carry out the following cell therapy technologies: CIK, CTL, NK, Tcm, DC-CIK, etc. In addition, we are working on the development of CAR-T cells related to hepatocellular carcinoma. Depending on the disease type, patient’s condition and immune system status, the main clinical applications of cell therapy include adjuvant therapy, i.e. cell therapy as an adjuvant to traditional surgery, minimally invasive, chemotherapy and radiotherapy to improve the efficacy, promote the removal of residual tumor cells, delay the time of recurrence or metastasis, and prolong OS; salvage or palliative therapy, i.e. for patients who cannot receive or are not suitable for other treatments, try to use cell therapy for salvage or palliative treatment. The aim of treatment is to relieve symptoms, improve survival treatment, and prolong survival time; monitoring index means follow-up according to the time and principles of oncology specialties, including tumor markers and imaging review; treatment course means using DC-CIK to sort peripheral blood single nuclei cells and then culture them, the culture time (1 course of treatment) is 14 days in total, day 7, 9, 11, 13, total NK cells are cultured for two weeks and the collected cells are returned on days 13 and 14. CTL are cultured for 3 weeks and returned on days 13, 17 and 21.